semaglutide and cardiovascular disease in Cardiometabolic Diseases: SELECTing the Target Population 💉 The FDA has approved

Preserves youthful skin

Real-world outcomes suggest patients with genetic GLP1R or GIPR variants benefit from this dual-compound approach, particularly when monotherapy plateaus

D1 S2:API Characterization and Sameness Demonstration Format: Presentations and a Panel Discussion with Q&A (Virtual and In-Person Attendees) This session establishes regulatory expectations and scientific approaches for demonstrating API sameness in generic GLP-1 peptide products

The FDA has lately expressed concerns over compounded semaglutide formulations and the risk of gastrointestinal complications, including ileus, underscoring the need of appropriate prescribing and monitoring practices (Lambson et al

2 reported that the monthly prevalence of obesity in U.S

While rodent studies showed thyroid C-cell tumors, clinical trials and post-marketing surveillance involving millions of patients have not established a causal link between semaglutide and medullary thyroid carcinoma in humans